Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRBU
stocks logo

CRBU

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.90M
-8.75%
-0.323
-17.22%
2.65M
+12.62%
-0.330
-23.26%
2.65M
-0.64%
-0.345
-40.52%
Estimates Revision
The market is revising Downward the revenue expectations for Caribou Biosciences, Inc. (CRBU) for FY2025, with the revenue forecasts being adjusted by -5.37% over the past three months. During the same period, the stock price has changed by 3.74%.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.88%
In Past 3 Month
Stock Price
Go Up
up Image
+3.74%
In Past 3 Month
Wall Street analysts forecast CRBU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBU is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CRBU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBU is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.940
sliders
Low
7.00
Averages
8.50
High
10.00
Current: 1.940
sliders
Low
7.00
Averages
8.50
High
10.00
H.C. Wainwright
Buy
maintain
$3 -> $9
2025-11-05
Reason
H.C. Wainwright
Price Target
$3 -> $9
2025-11-05
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Caribou Biosciences to $9 from $3 and keeps a Buy rating on the shares. The firm cites the new data for vispa-cel and CB-011 for the target increase.
Citi
Buy
maintain
$5 -> $8
2025-11-03
Reason
Citi
Price Target
$5 -> $8
2025-11-03
maintain
Buy
Reason
Citi raised the firm's price target on Caribou Biosciences to $8 from $5 and keeps a Buy rating on the shares, citing "meaningfully increased conviction" in the allogenic CAR-T value proposition following two "strong" data readouts in patients with relapsed or refractory B cell non-Hodgkin lymphoma and with relapsed or refractory multiple myeloma. The results deliver on previously communicated goals to generate continued allogenic efficacy on par with auto CAR-Ts and bispecifics, the analyst tells investors.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$9
2025-03-19
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$9
2025-03-19
Reiterates
Strong Buy
Reason
B of A Securities
Alec Stranahan
Strong Buy
Maintains
$13 → $11
2025-01-07
Reason
B of A Securities
Alec Stranahan
Price Target
$13 → $11
2025-01-07
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Caribou Biosciences Inc (CRBU.O) is -1.43, compared to its 5-year average forward P/E of -4.11. For a more detailed relative valuation and DCF analysis to assess Caribou Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.11
Current PE
-1.43
Overvalued PE
-0.02
Undervalued PE
-8.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.88
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.61
Undervalued EV/EBITDA
-6.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
31.45
Current PS
0.00
Overvalued PS
57.79
Undervalued PS
5.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1731.04% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CRBU News & Events

Events Timeline

(ET)
2025-11-12
17:24:15
Caribou Biosciences announces Q3 earnings per share of 30 cents, compared to a loss of 38 cents in the same period last year.
select
2025-11-11 (ET)
2025-11-11
16:27:07
Richard Pazdur Named Director of CDER by FDA
select
link
2025-11-03 (ET)
2025-11-03
07:15:53
Caribou Biosciences Reveals Findings from Phase 1 CaMMouflage Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Newsfilter
Caribou Biosciences Hosts Panel on vispa-cel to Broaden Patient Access for CAR-T Therapy
  • Expert Panel Discussion: Caribou Biosciences will host a panel on December 6, 2025, to discuss how vispa-cel can promote CAR-T therapy in community hospitals, thereby expanding patient access and enhancing the company's influence in oncology treatment.
  • Clinical Trial Progress: As of September 2025, 84 patients have been treated in the ANTLER trial, demonstrating that vispa-cel's safety and efficacy are comparable to autologous CAR-T therapies, which is expected to bolster the company's competitive position in the market.
  • Innovative Treatment Approach: Vispa-cel is the first allogeneic CAR-T therapy in clinical use with a PD-1 knockout, aimed at improving therapeutic efficacy, potentially transforming the treatment landscape for patients with large B-cell lymphoma and increasing market appeal for the company's products.
  • Regulatory Recognition: The FDA has granted vispa-cel several key designations, including Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug status, further enhancing its market potential and investment attractiveness.
[object Object]
Preview
2.0
11-04TipRanks
Three Penny Stocks to Keep an Eye on as of November 4, 2025

  • Penny Stocks to Watch: Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are highlighted as top penny stocks to monitor on November 4, 2025, based on their high Dollar Volume and market activity.

  • Generation Essentials Group: This France-based media company saw a Dollar Volume of $308 million and a 123% stock price increase after announcing a share repurchase program and plans to acquire hotels globally.

  • Phio Pharmaceuticals: The biotech firm experienced a Dollar Volume of $301.44 million despite a 9.3% decline in stock price, following positive trial results for its cancer treatment, which initially surged by nearly 75%.

  • Caribou Biosciences: With a Dollar Volume of $166.10 million, Caribou's stock reached a 52-week high after positive analyst ratings and promising data on its CRISPR gene-editing therapies for difficult-to-treat cancers.

[object Object]
Preview
1.0
11-04Newsfilter
Caribou Biosciences to Attend Upcoming Investor Conferences

  • Investor Conferences Participation: Caribou Biosciences, Inc. will participate in the 2025 Truist Securities BioPharma Symposium on November 6 and the 8th Annual Evercore Healthcare Conference on December 2, 2025, with a fireside chat scheduled for 8:45-9:05 AM ET.

  • Webcast Availability: Webcasts of the events will be accessible on Caribou's website for at least 30 days following each conference.

  • Company Overview: Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing therapies for severe diseases using its advanced genome-editing platform.

  • Therapeutic Focus: The company is concentrating on off-the-shelf CAR-T cell therapies, specifically vispacabtagene regedleucel (vispa-cel) and CB-011, aimed at providing rapid treatment options for patients with hematologic malignancies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Caribou Biosciences Inc (CRBU) stock price today?

The current price of CRBU is 1.94 USD — it has increased 4.3 % in the last trading day.

arrow icon

What is Caribou Biosciences Inc (CRBU)'s business?

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

arrow icon

What is the price predicton of CRBU Stock?

Wall Street analysts forecast CRBU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBU is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Caribou Biosciences Inc (CRBU)'s revenue for the last quarter?

Caribou Biosciences Inc revenue for the last quarter amounts to 2.20M USD, increased 8.60 % YoY.

arrow icon

What is Caribou Biosciences Inc (CRBU)'s earnings per share (EPS) for the last quarter?

Caribou Biosciences Inc. EPS for the last quarter amounts to -0.30 USD, decreased -21.05 % YoY.

arrow icon

What changes have occurred in the market's expectations for Caribou Biosciences Inc (CRBU)'s fundamentals?

The market is revising Downward the revenue expectations for Caribou Biosciences, Inc. (CRBU) for FY2025, with the revenue forecasts being adjusted by -5.37% over the past three months. During the same period, the stock price has changed by 3.74%.
arrow icon

How many employees does Caribou Biosciences Inc (CRBU). have?

Caribou Biosciences Inc (CRBU) has 147 emplpoyees as of December 05 2025.

arrow icon

What is Caribou Biosciences Inc (CRBU) market cap?

Today CRBU has the market capitalization of 181.33M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free